(Total Views: 315)
Posted On: 05/11/2023 10:33:00 AM
Post# of 30067
AMBS PIPELINE
AMBS has over 138 patents, licenses, options to license/patent assays in its product pipeline, and they hold rights to other intellectual property as well.
MANF: AMBS has obtained worldwide rights to MANF covering all neurological indications. They include but are not limited to:
1). Parkinson's Disease (PD)
2). Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease -
3). Ischemic Heart Disease
4). Alzheimer's Disease (AD)
5). Huntington's Disease
6). Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)
http://ir.amarantus.com/company-news/detail/9...-discovery
MANF: AMBS has entered into a license agreement with University of Miami Bascom-Palmer Eye Institute (ranked #1 in the U.S.) giving them rights to assays for the following indications:
7). Retinitis Pigmentosa (RP); and,
. other Inherited Retinal Disorders
9). Age related macular degeration
10). Glaucoma
11). Sporadic Retinal Disorders
12). Other degenerative disorders and retinal injury
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...-disorders
MANF: AMBS has a license agreement with Washington University for assays covering the following indications:
13). Wolfram's Syndrome
14). Diabetes Type-1
The third paragraph.
http://ir.amarantus.com/company-news/detail/1...f-medicine
On Dec. 26, 2012, AMBS obtained the entire Power3 Medical Products Intellectual Property (IP) portfolio covering 20 patents and all other IP rights:
15-34).
Quote:
12/802,630 – Diagnosis of Parkinson's Disease
13/118,175 – Assays for diagnosis and therapeutics...ALS and Parkinson's Disease
12/069,807 – 47 Protein Biomarkers for Neurodegenerative Diseases
12/804,868 – Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders
13/153,669 – Diagnosis of Alzheimer's Disease
As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia (CML).
Read More: https://investorshangout.com/post/view?
Posted by Hoosier 2015
id=2824848#ixzz81PeFZmWc
AMBS has over 138 patents, licenses, options to license/patent assays in its product pipeline, and they hold rights to other intellectual property as well.
MANF: AMBS has obtained worldwide rights to MANF covering all neurological indications. They include but are not limited to:
1). Parkinson's Disease (PD)
2). Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease -
3). Ischemic Heart Disease
4). Alzheimer's Disease (AD)
5). Huntington's Disease
6). Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)
http://ir.amarantus.com/company-news/detail/9...-discovery
MANF: AMBS has entered into a license agreement with University of Miami Bascom-Palmer Eye Institute (ranked #1 in the U.S.) giving them rights to assays for the following indications:
7). Retinitis Pigmentosa (RP); and,
. other Inherited Retinal Disorders 9). Age related macular degeration
10). Glaucoma
11). Sporadic Retinal Disorders
12). Other degenerative disorders and retinal injury
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...-disorders
MANF: AMBS has a license agreement with Washington University for assays covering the following indications:
13). Wolfram's Syndrome
14). Diabetes Type-1
The third paragraph.
http://ir.amarantus.com/company-news/detail/1...f-medicine
On Dec. 26, 2012, AMBS obtained the entire Power3 Medical Products Intellectual Property (IP) portfolio covering 20 patents and all other IP rights:
15-34).
Quote:
12/802,630 – Diagnosis of Parkinson's Disease
13/118,175 – Assays for diagnosis and therapeutics...ALS and Parkinson's Disease
12/069,807 – 47 Protein Biomarkers for Neurodegenerative Diseases
12/804,868 – Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders
13/153,669 – Diagnosis of Alzheimer's Disease
As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia (CML).
Read More: https://investorshangout.com/post/view?
Posted by Hoosier 2015
id=2824848#ixzz81PeFZmWc
(1)
(0)
